You are viewing the site in preview mode
Skip to main content
| |
MSI-H GC
|
MSS GC
| |
|---|
|
n = 185 (10.5%)
|
n = 1572 (89.5%)
|
p value
|
|---|
|
Sex, n (%)
| | |
< 0.001
|
|
Male
|
103 (55.7)
|
1088 (69.2)
| |
|
Female
|
82 (44.3)
|
484 (30.8)
| |
|
Age [y], median (quartile)
|
67 (60–73)
|
62 (54–69)
|
< 0.001
|
|
Tumor location, n (%)
| | |
< 0.001
|
|
Antrum and pylorus
|
125 (67.6)
|
713 (45.4)
| |
|
Angular
|
23 (12.4)
|
184 (11.7)
| |
|
Corpus
|
22 (11.9)
|
366 (23.3)
| |
|
Fundus and cardia
|
15 (8.1)
|
309 (19.7)
| |
|
Neoadjuvant therapy, n (%)
| | |
0.166
|
|
No
|
165 (89.2)
|
1343 (85.4)
| |
|
Yes
|
20 (10.8)
|
229 (14.6)
| |
|
Extent of lymphadenectomy
| | |
0.499
|
|
D1+ lymphadenectomy
|
22 (11.9)
|
221 (14.1)
| |
|
D2 lymphadenectomy
|
163 (88.1)
|
1351 (85.9)
| |
|
Tumor size [cm], median (quartile)
|
4 (2–6.5)
|
3 (2–4.8)
|
< 0.001
|
|
Pathology type, n (%)
| | |
< 0.001
|
|
Well-differentiated adenocarcinoma
|
66 (35.7)
|
425 (27.0)
| |
|
Moderately and poor-differentiated adenocarcinoma
|
67 (36.2)
|
554 (35.2)
| |
|
Mucinous adenocarcinoma
|
31 (16.8)
|
100 (6.4)
| |
|
Signet ring cell carcinoma
|
21 (11.4)
|
493 (31.4)
| |
|
Tumor stage, n (%)
| | |
0.205
|
|
Early GC
|
47 (25.4)
|
470 (29.9)
| |
|
Advanced GC
|
138 (74.6)
|
1102 (70.1)
| |
|
T stage, n (%)
| | |
0.600
|
|
Tis and T1
|
47 (25.4)
|
470 (29.9)
| |
|
T2
|
36 (19.5)
|
236 (15.0)
| |
|
T3
|
34 (18.4)
|
167 (10.6)
| |
|
T4
|
68 (36.8)
|
699 (44.5)
| |
|
Lymphovascular emboli, n (%)
| | |
0.002
|
|
No
|
97 (52.4)
|
1008 (64.1)
| |
|
Yes
|
88 (47.6)
|
564 (35.9)
| |
|
Perineural invasion, n (%)
| | |
< 0.001
|
|
No
|
138 (74.6)
|
955 (60.8)
| |
|
Yes
|
47 (25.4)
|
617 (39.2)
| |
|
Tumor deposit, n (%)
| | |
0.009
|
|
No
|
180 (97.3)
|
1445 (91.9)
| |
|
Yes
|
5 (2.7)
|
127 (8.1)
| |
|
PLNC, median (quartile)
|
0 (0–3)
|
2 (0–7)
|
< 0.001
|
|
NLNC, median (quartile)
|
27 (21–35)
|
23 (16–32)
|
< 0.001
|
|
N stage, n (%)
| | |
< 0.001
|
|
N0
|
95 (51.4)
|
630 (40.1)
| |
|
N1
|
33 (17.8)
|
239 (15.2)
| |
|
N2
|
30 (16.2)
|
276 (17.6)
| |
|
N3a
|
19 (10.3)
|
259 (16.5)
| |
|
N3b
|
8 (4.3)
|
168 (10.7)
| |
|
M stage, n (%)
| | |
0.002
|
|
M0
|
185 (100.0)
|
1495 (95.1)
| |
|
M1
|
0 (0.0)
|
77 (4.9)
| |
|
AJCC stage, n (%)
| | |
0.005
|
|
I
|
68 (36.8)
|
545 (38.9)
| |
|
II
|
57 (30.8)
|
298 (19.1)
| |
|
III
|
60 (32.4)
|
652 (40.4)
| |
|
IV
|
0 (0.0)
|
77 (4.9)
| |
- MSI microsatellite instability
- MSS microsatellite stability
- GC gastric cancer
- PLNC positive lymph node count
- NLNC negative lymph node count
